SurroMed has initiated preclinical proof-of-principle studies with several candidate therapeutic products, that address significant unmet medical needs.

SurroMed is seeking to in-license additional therapeutic candidates with a focus in the areas of autoimmune and inflammatory disease. We are particularly interested in therapeutic candidates whose development or commercial success could be enhanced by application of our biomarker discovery technology. Examples of such applications include identification of responder populations and easy stratification procedures.